ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

AVXL Anavex Life Sciences Corporation

3,44
0,05 (1,47%)
27 Apr 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Anavex Life Sciences Corporation AVXL NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,05 1,47% 3,44 01:48:08
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
3,40 3,37 3,48 3,44 3,39
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
26.4.202411:45PRNUSMay 13, 2024 Deadline: Contact The Gross Law Firm to Join..
19.4.202411:45PRNUSContact The Gross Law Firm by May 13, 2024 Deadline to Join..
16.4.202411:45PRNUSThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff..
12.4.202411:45PRNUSClass Action Filed Against Anavex Life Sciences Corporation..
11.4.202413:30GLOBEAnavex Life Sciences to Present at the Noble Capital Markets..
09.4.202411:45PRNUSClass Action Filed Against Anavex Life Sciences Corporation..
05.4.202411:45PRNUSAnavex Life Sciences Corporation Class Action: The Gross Law..
02.4.202411:45PRNUSShareholders that lost money on Anavex Life Sciences..
29.3.202410:45PRNUSLost Money on Anavex Life Sciences Corporation(AVXL)? Join..
26.3.202410:45PRNUSInvestors who lost money on Anavex Life Sciences..
25.3.202412:30GLOBEAnavex Life Sciences to Present at the 23rd Annual Needham..
22.3.202410:45PRNUSAVXL LAWSUIT ALERT: The Gross Law Firm Notifies Anavex Life..
18.3.202412:30GLOBEAnavex Life Sciences Initiates Placebo-Controlled U.S. Phase..
26.2.202413:30GLOBEAnavex Life Sciences to Present at the 44th Annual TD Cowen..
23.2.202412:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23.2.202412:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23.2.202412:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23.2.202412:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23.2.202412:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.2.202422:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07.2.202413:30GLOBEAnavex Life Sciences Reports Fiscal 2024 First Quarter..
01.2.202413:30GLOBEAnavex Life Sciences to Announce Fiscal 2024 First Quarter..
25.1.202423:01EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
24.1.202413:30GLOBEAnavex Life Sciences Reports Publication of ANAVEX®3-71 in..
16.1.202413:30GLOBEAnavex Life Sciences Announces U.S. Phase 2 Clinical Trial..
13.1.202402:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.1.202413:30GLOBEAnavex Life Sciences Announces Grant of U.S. Patent Covering..
03.1.202413:30GLOBEAnavex to Present at the 42nd Annual J.P. Morgan Healthcare..
02.1.202414:00GLOBEAnavex Life Sciences Provides an Update on Rett Syndrome..
20.12.202313:30GLOBEAnavex Announces First Entire Clinical Gene Pathway Data of..
19.12.202313:30GLOBEAnavex Received Agreement from the Committee for Medicinal..
27.11.202322:30EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27.11.202314:00GLOBEAnavex Life Sciences Reports Fiscal 2023 Year End Financial..
27.11.202312:29IHMARKETNEWSMonday’s Wall Street Highlights: Walmart, Disney, Lloyds..
24.11.202314:00GLOBEAnavex Life Sciences to Announce Fiscal 2023 Year End..
22.11.202314:00GLOBEAnavex Life Sciences Announces Grant of U.S. Patent Covering..
20.11.202314:00GLOBEAnavex Initiates Regulatory Submission of Oral Blarcamesine..
06.11.202314:00GLOBEAnavex Life Sciences Appoints Senior VP of Regulatory..
25.10.202314:00GLOBEAnavex Life Sciences Reports New Publication in Scientific..
14.9.202313:30GLOBEAnavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in..
12.9.202313:30GLOBEAnavex Announces Appointment of Dr. Marwan N Sabbagh, MD as..
08.8.202322:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08.8.202313:30GLOBEAnavex Life Sciences Reports Fiscal 2023 Third Quarter..
07.8.202313:30GLOBEAnavex Life Sciences Reports Publication of ANAVEX®3-71 in..
02.8.202313:30GLOBEAnavex Life Sciences to Present at the BTIG Virtual..
01.8.202313:30GLOBEAnavex Life Sciences to Announce Fiscal 2023 Third Quarter..
28.6.202313:30GLOBELong-term Clinical Study Demonstrates Disease Modifying..
27.6.202313:30GLOBEAnavex Life Sciences and Partex Group Announce Strategic..
20.6.202313:30GLOBEAnavex Life Sciences to Present at the H.C. Wainwright 4th..
15.6.202313:30GLOBEANAVEX®2-73 (blarcamesine) Receives Compassionate Use..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock